Jubilant Life Sciences Ltd - 530019 - USFDA Inspection Update - API Facility At Nanjangud
Dear Sirs, We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take the same on record. Jubilant Life gets USFDA warning letter for Roorkee facility
`Warning letter' means a notification issued by FDA to manufacturer who significantly violated its regulations JUBILANT LIFE SCIENCES LIMITED - 530019 - USFDA Warning Letter For Roorkee Facility, India
Dear Sirs, We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take the same on record. JUBILANT LIFE SCIENCES LIMITED - 530019 - Sub: Intimation Pursuant To Regulation 57(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dear Sirs, This is to certify that the Company has duly paid half yearly interest for Non-Convertible Debentures - STRPP 1, STRPP 2 and STRPP 3 issued on private placement basis on the due date as per details attached. This is for your information and records. JUBILANT LIFE SCIENCES LIMITED - 530019 - Sub: Issuance Of Rated Unsecured Bonds Of US$200 Million By Our Wholly-Owned Subsidiary Jubilant Pharma Limited (A Company Incorporated Under The Laws Of Singapore), Outside India, Under Regulation S Of The U.S. Securities Act Of 1933, As Amended.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and further to the disclosure made to the stock exchanges on March 5, 2019, where we have informed about successful completion of the offering of rated unsecured bonds (the 'Notes') of an aggregate principal amount of US$200 million, by our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore), outside India to institutional investors outside India under Regulation S of the U.S. Securities Act of 1933, as amended, we would like to inform that the Notes have been listed and quoted on the Official List of the Singapore Exchange Securities Trading Limited on March 6, 2019. With this letter, we have attached the final Offering Memorandum filed with the Singapore Exchange Securities Trading Limited in connection with the issuance of the Notes. The above is for your information and records. We request you to take the same on record. Jubilant Life Sciences Ltd - 530019 - Sub: Issuance Of Rated Unsecured Bonds Of US$200 Million By Our Wholly-Owned Subsidiary Jubilant Pharma Limited (A Company Incorporated Under The Laws Of Singapore), Outside India, Under Regulation S Of The U.S. Securities Act Of 1933, As Amended.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and further to the disclosures made to the stock exchanges earlier in this regard, we wish to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore) ('JPL') has successfully completed today i.e. March 5, 2019, the issuance of rated unsecured bonds (the 'Notes') to institutional investors outside India under Regulation S of the U.S. Securities Act of 1933, as amended, bearing interest at 6.00% per annum. The Notes were issued at par in a principal amount of US$200 million and will mature in March, 2024. The Joint Global Coordinators, Joint Lead Managers and Joint Bookrunners to the issue of the Notes are DBS Bank Ltd., J.P. Morgan (S.E.A.) Limited and UBS AG, Singapore Branch. The above is for your information and records. The Company will provide further updates in this regard, if and when necessary. We request you to take the same on record. Jubilant Life Sciences Ltd - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sub. : Intimation of Investor/ Analyst Meetings on March 6, 2019 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be meeting Investor/ analysts in Mumbai, India on March 6, 2019. We enclose details of analyst meetings scheduled for the same. The schedule may undergo change due to exigencies on the part of Investor/ Analysts/ Company. We also enclose the presentation to be used during the meetings. This is for your kind information and records. Jubilant Life Sciences Ltd - 530019 - Issuance Of Rated Unsecured Bonds By Our Wholly-Owned Subsidiary Jubilant Pharma Limited (A Company Incorporated Under The Laws Of Singapore), Outside India, Under Regulation S Of The U.S. Securities Act Of 1933, As Amended.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and further to the disclosure made to the stock exchanges on February 25, 2019, we wish to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore) ('JPL') has successfully priced its rated unsecured bonds (the 'Notes') at 6.00% per annum issued at par for US$200 million maturing in March, 2024. S&P; Global Ratings ('S&P;') has affirmed BB-/positive rating and Fitch Ratings ('Fitch') has affirmed BB-/Stable rating for JPL (the issuer of the Notes). The Notes have been rated BB- by S&P; and BB by Fitch. The major portion of the net proceeds of the Notes shall be used to refinance existing indebtedness and pay associated fees and premiums over a period of time and the balance amount for working capital and general corporate purposes. The above is for your information and records. The Company will provide further updates in this regard, if and when necessary. We request you to take the same on record. Jubilant Life Sciences (784.5): Buy
Gurumurthy K The outlook for the stock of Jubilant Life Sciences is bullish. The stock rose over 2 per cent on Thursday breaking above a key resistan Jubilant Life Sciences Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that share certificate has been reported to be lost by the shareholder as per attached letter. The shareholders have requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the shareholders on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record.